Benzinga

Benzinga

Benzinga

mercoledì, agosto 26

Kiniksa Pharmaceuticals International PLC

KNSANASDAQ
Trade with Public
Trade with Public
$80.20
0.821.03%
In chiusura: Aug 24, 5:00 PM EST
$80.49
1.111.4%
Pre-mercato: 7:13 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Kiniksa Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kiniksa Pharmaceuticals (KNSA).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

9Buy
Consensus RatingBuy# Analysts9Avg. Consensus PT$82Upside to Avg. PT+1.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 30, 2026Goldman SachsPaul ChoiPT RaiseBuy$75→$90
Jul 29, 2026JP MorganAnupam RamaPT RaiseOverweight$72→$107
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $90

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $75 to $90.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $107

JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $72 to $107.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $64 to $98.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $99

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $72 to $99.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $100

Citigroup analyst Geoff Meacham maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $100.
Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved